S. 1717 119th Congress
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Latest action, May 12, 2025: Read twice and referred to the Committee on Finance.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
5 cosponsors
Sponsored by Todd Young (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
3 D · 2 R
- Democrat
- Republican
- Independent
Referred to: Senate: Finance Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION
EMERGENT STRATEGIES
6 reports
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED)
THE NICKLES GROUP, LLC
6 reports
6 reports
EDWARDS LIFESCIENCES LLC
AVENUE SOLUTIONS
6 reports
MEDICAL DEVICE MANUFACTURERS ASSOCIATION
THE MCMANUS GROUP
6 reports
6 reports
6 reports
6 reports
ROCHE DIAGNOSTICS
THE MCMANUS GROUP
6 reports
6 reports
5 reports
5 reports
5 reports
All 25 of 29 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | EMERGENT STRATEGIES | 6 | $90K | Q4 2025 | Q3 2026 | yes |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | THE NICKLES GROUP, LLC | 6 | $360K | Q4 2025 | Q3 2026 | yes |
| EDWARDS LIFESCIENCES LLC | 6 | $1.9M | Q4 2025 | Q3 2026 | yes | |
| EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES | 6 | $620K | Q4 2025 | Q3 2026 | yes | |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 6 | $1.9M | Q4 2025 | Q3 2026 | yes | |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | THE MCMANUS GROUP | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| MEDTRONIC INC | 6 | $7.5M | Q4 2025 | Q3 2026 | yes | |
| NOVOCURE INC. | 6 | $830K | Q4 2025 | Q3 2026 | yes | |
| PHILIPS HOLDING USA INC. | 6 | $3.6M | Q4 2025 | Q3 2026 | yes | |
| ROCHE DIAGNOSTICS | THE MCMANUS GROUP | 6 | $240K | Q4 2025 | Q3 2026 | yes |
| THE COOK GROUP INC. | 6 | $800K | Q4 2025 | Q3 2026 | yes | |
| ADVANCED MEDICAL TECHNOLOGY ASSN | 5 | $5.0M | Q4 2025 | Q3 2026 | yes | |
| BOSTON SCIENTIFIC CORPORATION | 5 | $3.1M | Q4 2025 | Q3 2026 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 5 | $11.2M | Q4 2025 | Q3 2026 | yes | |
| LIFE SCIENCES PENNSYLVANIA | 5 | $6,000 | Q4 2025 | Q3 2026 | yes | |
| SIEMENS MEDICAL SOLUTIONS USA, INC | 5 | $3.8M | Q4 2025 | Q2 2026 | yes | |
| JOHNSON & JOHNSON SERVICES, INC. | ML STRATEGIES, LLC | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| NOVOCURE INC. | WILLIAMS AND JENSEN, PLLC | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| ZIMMER BIOMET | THE MCMANUS GROUP | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| ALZHEIMER'S ASSOCIATION | 3 | $3.7M | Q1 2026 | Q3 2026 | yes | |
| NATIONAL HEALTH COUNCIL | 3 | $63K | Q4 2025 | Q3 2026 | yes | |
| SIEMENS MEDICAL SOLUTIONS USA, INC. | AVENUE SOLUTIONS | 3 | $0 | Q1 2026 | Q3 2026 | yes |
| THERMO FISHER SCIENTIFIC INC | 3 | $1.5M | Q1 2026 | Q3 2026 | yes | |
| EXACT SCIENCES | 2 | $870K | Q4 2025 | Q3 2025 | yes |